Form 4: BioXcel Therapeutics CFO Richard Steinhart Reports Stock Transactions
SEC Form 4 Filing
Richard Steinhart, CFO of BioXcel Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- On June 14, 2024, Richard Steinhart, the CFO of BioXcel Therapeutics, acquired 521 shares of common stock through the vesting of restricted stock units (RSUs) and disposed of 372 shares at a price of $1.2622 on June 17, 2024.
- On June 15, 2024, he acquired 562 shares of common stock through RSU vesting.
- These transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2023.
- Following these transactions, Steinhart directly owns 5,476 shares of common stock and 6,188 restricted stock units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions by an insider under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's future.
Industry Context
Form 4 filings are standard disclosures required by the SEC for corporate insiders, providing transparency into their trading activities. These filings are closely watched by investors for signals about a company's prospects.
Stakeholder Impact
- Shareholders may be interested in the CFO's transactions as an indicator of management's view of the company's stock.
Key Dates
| Date | Description |
|---|---|
| 2022-03-14 | Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| 2023-03-15 | Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| 2023-12-14 | Date the Reporting Person adopted a Rule 10b5-1 trading plan. |
| 2024-06-14 | Acquisition of 521 shares of common stock through RSU vesting. |
| 2024-06-15 | Acquisition of 562 shares of common stock through RSU vesting. |
| 2024-06-17 | Disposal of 372 shares of common stock at $1.2622 per share. |
| 2024-06-18 | Date of Form 4 filing. |
Keywords
BioXcel Therapeutics, BTAI, Richard Steinhart, CFO, Form 4, Stock Transactions, Restricted Stock Units, Rule 10b5-1 Trading Plan, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.